Sentences with phrase «treatment development study»
Guy S. Diamond, Brendali F. Reis, Gary M. Diamond, Lynne Siqueland, and Lisa Isaacs, «Attachment - Based Family Therapy for Depressed Adolescents: A Treatment Development Study,» Journal of the American Academy of Child and Adolescent Psychiatry, Vol.
http://www.promisingpractices.net/
A combined cognitive - behavioral family education intervention for depression in children: A treatment development study.
Comprehensive Behavioral Treatment of Trichotillomania: A Treatment Development Study.
He currently is conducting treatment development studies to determine if new approaches will increase the efficacy of depression treatments for adolescents.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
In 1965, he published his most famous book, at once classic and immediately consequential as a study in the development of doctrine: Contraception: A History of Its Treatment by the Catholic Theologians and Canonists — 533 pages of dazzling historical research, unpretentious erudition, and contextual analysis that concluded by offering reasons why the papal magisterium could and should support some forms of contraception for married couples.
If affirmed in human studies, the experiments could pave the way to new preventive approaches to stave off NEC in premature babies and spark the development of treatments for those who develop the condition.
less than or equal to lamivudine Acquired Immune Deficiency Syndrome Antiretroviral therapy, usually means 1 - 2 drugs, used in early studies Antiretroviral zidovudine (also known as ZDV) Breastfeeding Baby Friendly Hospital Initiative Breastfeeding and HIV International Transmission Study Combined antiretroviral therapy Centers for Disease Control and Prevention Deoxyribonucleic Acid Exclusive Breastfeeding Enzyme Linked Immunosorbent Assay Food and Agrigulture Organization Fixed dose combination ART, e.g., lamividine, stavudine, and nevirapine Highly Active Antiretroviral Therapy, 3 or more drugs for more effective treatment used in later studies Human Immunodeficiency virus International Atomic Energy Agency Infant feeding Infant and young child feeding Lopinavir cubic millimetre Mother - to - Child Transmission of HIV Non-governmental organization Nevirapine Polymerase Chain Reaction People Living with HIV Prevention of Mother - to - Child Transmission Replacement Feeding Ritonavir Ribonucleic acid, one of the three major macromolecules (along with DNA and proteins) that are essential for all known forms of life single dose NVP United Nations Agencies Joint United Nations Programme on HIV / AIDS United Nations Population Fund United Nations Commissioner for Refugees United Nations Children's Fund U.S. Agency for International Development World Alliance for Breastfeeding Action United Nations World Food Programme World Health Assembly WHO 2010 Guidelines on HIV and infant feeding World Health Organization Zidovudine (same drug as AZT)
This study represents a significant step towards the development of clinical trials in gene therapy for the curative treatment of hereditary deafness and balance loss in humans.
Through studies on rats and mice, he and his colleagues have come up with new findings that may be significant to the development of new treatment methods.
On the scientific agenda are identifying molecular markers for resistance, which would simplify testing; accelerating the development of alternative drugs; and studying the effectiveness of mass screening and treatment to eliminate malaria in the areas where resistance occurs.
The first study will examine these patients over time, in order to analyze other important variables such as melanoma relapse, mortality, resistance to treatment, development of a second melanoma or other cancers, and metastasis, including spread of the cancer to nearby lymph nodes (sentinel nodes).
GIS's DNA analysistechnique has allowed the researchers to further study the biology of Opisthorchis viverrini to understand the cause and the eventual development of treatments for bile duct cancer, a condition caused by the parasite.
Nevertheless, the results identify key factors to consider during the transition from long - term residential treatment to the community, and the findings from this study will inform future intervention development that aims to significantly improve mid-range and long - term outcomes among people with SUDs leaving residential treatment.
One such treatment is already under development for testing in humans after the current study showed it stopped nerve cell damage in mice with ALS.
The Myelin Repair Foundation, which funded this work as part of a multi-institutional effort to accelerate research and development of treatments for MS, has entered into a cooperative agreement with the National Institutes of Health to assess guanabenz as a therapeutic candidate in MS clinical studies.
The study is part of a research project led by professors Dominique de Quervain and Andreas Papassotiropoulos at the University of Basel, which aims to increase the understanding of neuronal and molecular mechanisms of human memory and thereby facilitate the development of new treatments.
«More people than ever are surviving cancer due to the development of targeted and effective treatments,» said Shelley Johns, Psy.D., the clinical health psychologist and health services researcher who led the Regenstrief - IU study.
Further studies of this interaction could provide clues for the development of new treatments to combat P. aeruginosa infection.
«This diagnosis method is a way of identifying those patients who are more likely to develop metastasis, so that their treatment and survival can be improved.This study could also open up new avenues of research for the development of new, more personalized treatments,» explained Dr Arroyo.
Such an understanding is urgently needed, as no treatments are yet available for muscular dystrophies and muscle - wasting disorders,» stated Alessandra Sacco, Ph.D., associate professor in the Development, Aging, and Regeneration Program at SBP and senior author of the study.
Using endophytic fungi to illustrate, Hawkes and Connor discuss the integration of ecological and evolutionary niche theory in plant microbiome studies to help with the development and implementation of microbiome treatments.
By more fully elucidating the role of serotonin in the brain, this study may contribute to a better understanding of the development or treatment of these conditions.
Most importantly for individuals with FOP, the study identifies HIF - 1α as a therapeutic target — knowledge that will likely contribute to the development of more effective treatments for FOP and related common disorders of heterotopic ossification.
«This study offers new insights about the brain in AN, which we are using to guide treatment development efforts, and reduce stigma associated with this life - threatening disorder,» added Kaye, who is a Professor of Psychiatry and Director of the Eating Disorder Program at UCSD.
With approximately two - thirds of responders to AF - 219 treatment showing more than a 50 % reduction in cough frequency, we plan to advance the development of AF - 219 by initiating a Phase 2b study in patients with chronic cough early next year and to initiate other studies in preparation for registration studies.»
«While we studied patients with allergic asthma, this research opens the door for the development of new treatments not only for this population, but for those diagnosed with severe asthma as well.»
In the 1980s and 1990s, for example, Frederick Hayden of the University of Virginia School of Medicine in Charlottesville conducted challenge studies with influenza that helped speed the development of Tamiflu and Relenza, drugs that have become the mainstays of treatment.
«We hope that our findings will foster development of a personalized strategy for the prevention and treatment of multiple sclerosis, one that takes into account the gender - specific contribution of galanin gene variants to susceptibility and disease progression,» said Dr. Victoria Lioudyno, lead author of the study.
«This study opens a promising new avenue of research into treatments that may prevent the development of epilepsy,» said Vicky Whittemore, PhD, a program director at the National Institute of Neurological Disorders and Stroke, who oversees the grants that funded this study.
By matching normal and cancer cells from a patient, we can now study the differences — what molecules are key to tumor development and growth, and, ultimately, match treatments that might disable this cancer,» says the study's senior investigator, associate professor of pathology, Xuefeng Liu, MD, a member of the Center for Cell Reprogramming (CCR) at Georgetown University Medical Center.
The approach could help researchers study mammalian sperm development more directly, and it could spur efforts to develop treatments for male infertility in people.
The study sets the stage for the development of more - sensitive and specific non-invasive tests for prostate cancer than those currently available, which could result in fewer unnecessary prostate biopsies with less treatment - related morbidity, according to a new study in The Journal of Molecular Diagnostics.
«Mouse and human kidney development compared: Findings may lead to advances in the study and treatment of kidney disease.»
In addition, municipal water treatment systems are unable to filter antibiotics, and are being studied for their impact on the development of resistance in the environment.
The study, to be published online in Cell on Oct. 31, offers a new theory of cancer development and could open the door for new treatment targets.
In a previous study, investigators at the Cancer Institute showed that using a vaccine treatment for bladder and breast cancer tumors in laboratory models resulted in a reversal of the traditional immune blockade, as well as the development of tumor specific immunity throughout the body.
The monoclonal antibody in this study is one of several antibodies targeting GD2 that are in clinical development for treatment of neuroblastoma.
The discovery means investigators now can grow both parts of the human stomach to study disease, model new treatments and understand human development and health in ways never before possible.
Abnormal levels of the proteins may be useful biomarkers that could help us study early treatments to limit or reverse the damage to brain cells and even prevent the development of the full - blown disease,» said study author Edward Goetzl, MD, a Professor of Medicine with the University of California, San Francisco, a researcher at the National Institute on Aging, and a scientist of NanoSomiX, Inc., a California - based biotechnology company that provided a grant for method development for the study.
The study also may have broader implications for how clinicians approach the development of such treatments and understand mechanisms behind resistance to treatment in other cancers.
Charles Akle, Chairman of Immodulon, said: «The results from this study are remarkable and represent a significant breakthrough in the development of immunotherapy for the treatment of pancreatic cancer.
«We really have all the pieces we need to move forward in the development of effective therapeutics,» says Paul Aisen, a neuroscientist at the University of California, San Diego, and director of the Alzheimer's Disease Cooperative Study — a 21 - year - old programme of government - funded clinical studies aimed at developing Alzheimer's treatments.
«This study shows how translational research using basic science techniques in animal models can elucidate the underlying basis of human emotions and reasons for mental disorders, thereby pointing the way for treatment development,» says Jeffrey Lieberman, MD, Lawrence C. Kolb Professor and Chair of Psychiatry at CUIMC.
«This concept has significant therapeutic implications and will drive the development of new therapies because it implies that MS will produce significant disability if suffered for enough time in all patients,» says co-author Dr. Pablo Villoslada, Head of the IDIBAPS research group in Pathogenesis and new treatments in multiple sclerosis and coordinator of the study.
«There are two benefits: The child can make progress, and the parents leave the treatment program better equipped to facilitate the child's development over the course of their daily routines,» said study co-author Grace Gengoux, PhD, clinical assistant professor of psychiatry and behavioral sciences and a psychologist specializing in autism treatment at the hospital.
«Continued study of the mechanisms involved in the development of alcohol - induced cardiac birth defects is warranted in order to implement effective treatments and / or prevention strategies.»
Guselkumab, a fully human monoclonal antibody targeting IL - 23, in this Phase 2 study for the treatment of PsA, was well tolerated with no unexpected safety findings in this patient population.2 Guselkumab is now being pursued in a Phase 3 development programme for psoriatic arthritis.
This research could also contribute to evolutionary studies to survey and understand genomes where no research has been done before, revealing important regulatory properties that may aid development of new products or disease treatments.
Published in the Journal of Psychosocial Oncology, «Development and Initial Evaluation of a Telephone - Delivered Behavioral Activation and Problem - solving Treatment Program to Address Functional Goals of Breast Cancer Survivors,» covers two studies looking at feasibility and potential efficacy.